These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33102342)

  • 21. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
    Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O
    PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
    Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
    Boss C; Bolli MH; Gatfield J
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3381-94. PubMed ID: 27321813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
    Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
    Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
    Channick RN; Delcroix M; Ghofrani HA; Hunsche E; Jansa P; Le Brun FO; Mehta S; Pulido T; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Galiè N
    JACC Heart Fail; 2015 Jan; 3(1):1-8. PubMed ID: 25457902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.
    Buendia JA; Patino DG; Lindarte EF
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):967-973. PubMed ID: 37403496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.
    Schweintzger S; Koestenberger M; Schlagenhauf A; Grangl G; Burmas A; Kurath-Koller S; Pocivalnik M; Sallmon H; Baumgartner D; Hansmann G; Gamillscheg A
    Cardiovasc Diagn Ther; 2020 Oct; 10(5):1675-1685. PubMed ID: 33224780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
    Martynyuk TV; Nakonechnikov SN; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review.
    Nahar S; Kanda S; Chatha U; Odoma VA; Pitliya A; AlEdani EM; Bhangu JK; Javed K; Manshahia PK; Yu AK
    Cureus; 2023 Jul; 15(7):e42748. PubMed ID: 37654961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
    Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.